Medical cannabis for Epidermolysis Bullosa – Dispatch Medical THC Store Mississauga Canada

Herb Approach

The bullous epidermolysis (EB) is a skin disorder characterized by the fragility of the skin, also known as "onion skin". However, this disease can manifest itself in many organ systems.

Children with bullous epidermolysis can have a multidisciplinary management for life with the support of dermatologists, cardiologists, hematologists / oncologists, nephrologists, dentists, ophthalmologists, nutritionists, pediatric speech therapists and speech therapists, neurologists, pain specialists, psychologists, social workers, community support, surgeons, gastroenterologists, medical scientists and scientists. In this sense, current treatments are intended to restore the integrity of the skin with protein, cell and genetic therapies.[1]

EB is caused by defects in the anchoring of proteins between the epidermis and the dermis, which predispose patients to bullae, blisters and scars, resulting in the mechanical fragility of the skin. There are four subtypes of EB in which the dermal-epidermal junction proteins are affected: simple EB, coyonational EB, dystrophic EB and Kindler syndrome.

Endocannabinoid system and bullous epidermolysis

Cannabidiol (CBD) is the second most abundant cannabinoid compound found in the cannabis plant after tetrahydrocannabinol (THC). CBD has no psychotic effects and has become popular among people with chronic pain, anxiety and sleep disorders.

In humans, there are two main cannabinoid receptors that have been identified: CB1 and CB2. Both interact with the CBD. CB1 is expressed primarily in the brain and spinal cord, while the CB2 receptor is expressed in immune cells, which reduces inflammation. This cannabinoid is also a direct agonist of vaniloid receptors, involved in pain, inflammation and body temperature.

It has been shown that cannabinoid agents indirectly inhibit the proliferation of cultured human epidermal keratinocytes and stimulate apoptosis. In fact, the treatment of acne vulgaris with cannabinoids has been documented due to the decrease in human sebocyte proliferation. Finally, the CB1 receptor has also been implicated in epidermal regulation of differentiation by inhibition of transglutaminase, protein kinase C and activation of protein-1.[2]

Topical CBD oil in children with bullous epidermolysis

In 2019, a clinical study analyzed 3 pediatric patients (6 months old, 3 and 10 years old) using topical CBD to treat bullous epidermolosis. The results reported that one patient stopped the oral opioid analgesic and all 3 reported faster wound healing, pain improvement and fewer blisters. However, more randomized double-blind clinical trials are needed to provide scientific benefits for Epidermolysis Bullosa[3].

CBD and sublingual THC in adults with EB

The CB1 and CB2 receptors have been detected in the human skin and in the presynaptic terminals of the primary circuits of afferent pain and are co-located with mu-opioid receptors at the spinal cord junction for peripheral nociceptive neurons. In addition, the activation of CB2 in keratinocytes produces a blocking response to certain harmful reactions through the release of endogenous opioids in peripheral tissues.[4]

In 2018, an article published in the British Journal of Dermatology did studies Three patients with quider epidermolysis bullosa were treated with THC and sublingual CBD, four times a day, along with your previous treatments. All three patients reported a better pain score as well as a reduction in the overall intake of analgesic drugs and reduction of pruritus.[5]

conclusion

So far, investigations notified in patients with bullous epidermolysis they are showing the potential that cannabinoids have to inhibit the proliferation of dangerous epidermal cells and induce their apoptosis, in addition to relieving pain and pruritus perception. However, more research and controlled studies are needed to adequately assess the doses and the correct specific administration method for the treatment of epidermolysis bullosa with medicinal cannabis.

Did you like this post? Make an assessment. This post has been made based on existing research until the date of publication of the article. Due to the increase in studies on medical cannabis, the information presented may vary over time and we will inform in subsequent writings.

[1] Cohn, H. I., & Teng, J. M. C. (2016). Advancement in management of epidermolysis bullosa. Current Opinion in Pediatrics, 28 (4), 507-516. doi: 10.1097 / mop.0000000000000380

[2] Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A, Finazzi-Agrò A. (2003). The Endocannabinoid System in Human Keratinocytes. The Journal of Biological Chemistry; 278 (36): 33896-33903. Doi: 10.1074 / jbc.m303994200

[3] Chelliah, M. P., Zinn, Z., Khuu, P., & Teng, J. M. C. (2018). Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatric Dermatology, 35 (4), e224 – e227.doi: 10.1111 / pde.13545

[4] Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008; 4: 245–59.

[5] Schräder, N. H. B., Duipmans, J. C., Molenbuur, B., Wolff, A., & Jonkman, M. F. (2018). Combined THC and CBD to treat pain in epidermolysis bullosa: a report of three cases. British Journal of Dermatology. doi: 10.1111 / bjd.17341

No votes yet.